Skip to main content

Table 2 Immune-reactivity score for expression of mTOR, p-mTOR, MMP2, MMP7, MMP9 in the tumor center and at the invasive front of type gastric cancer

From: MMP2 and MMP7 at the invasive front of gastric cancer are not associated with mTOR expression

Targets

Intestinal type (n = 86)

Diffuse type (n = 42)

Overall (N = 128)

 

Tumor center

Invasive front

p-value

Tumor center

Invasive front

p-value

Tumor center

Invasive front

p-value

MMP2

4.10 ± 5.042

7.65 ± 7.782

<0.001*

2.93 ± 3.925

5.40 ± 6.688

0.005*

3.72 ± 4.721

6.91 ± 7.490

<0.001*

MMP7

5.43 ± 8.345

4.48 ± 7.680

0.008*

5.10 ± 8.798

4.50 ± 7.613

(0.128)

5.32 ± 8.463

4.48 ± 7.628

0.002*

MMP9

4.57 ± 7.362

3.97 ± 7.058

(0.227)

5.62 ± 7.821

4.71 ± 6.656

(0.144)

4.91 ± 7.501

4.21 ± 6.912

(0.097)

mTOR

10.95 ± 7.543

9.79 ± 8.778

0.025*

8.67 ± 6.091

9.12 ± 6.463

(0.589)

10.20 ± 7.156

9.57 ± 8.072

(0.127)

p-mTOR

3.42 ± 4.185

2.69 ± 4.610

0.008*

2.13 ± 2.662

2.76 ± 4.667

(0.545)

3.00 ± 3.792

2.71 ± 4.610

0.013*

  1. Comparison between tumor center and invasive front has been done by the Mann–Whitney U-test with significant differences (p < 0.05) marked by an asterisk. Values are given as mean and standard deviation